Articles tagged "Rejection"

2015 American Transplant Congress
Late Rejection in Pediatric Heart Transplantation: The Importance of Medical Adherence
A. Letica, W. Zuckerman, L. Addonizio, J. McAllister, T. Lee, M. Richmond.
Division of Pediatric Cardiology, Columbia University, New York, NY.
While the incidence of early rejection (<1 yr post-transplant) after pediatric heart transplant (HT) has decreased, late rejection (> 1 yr post-transplant) remains a constant…
2015 American Transplant Congress
Long Term Outcomes of Tocilizumab Therapy for DSA+ Antibody Mediated Rejection (ABMR) Resistant to IVIG + Rituxan (I+R) Treatment
J. Choi,¹ A. Vo,¹ J. Kahwaji,¹ M. Haas,² N. Reinsmoen,³ D. Puliyanda,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹CTC, Cedars Sinai, Los Angeles, CA; ²Pathology, Cedars-Sinai, Los Angeles, CA; ³HLA Laboratory, Cedars-Sinai, Los Angeles, CA.
Intro: Limited options are available for treatment of ABMR in highly-HLA sensitized patients (HS). Treatment options include I+R, PLEX+I+/- R, C5-inhibitor & bortezomib. Approximately 25%…
2015 American Transplant Congress
The Significant Association Between the Functional Polymorphism (Rs3761548) of Foxp3 Gene and the Severity of Acute Cellular Rejection in Liver Transplantation
S. Verma, Y. Tanaka, S. Shimizu, L. Das, H. Ohdan.
Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Aim- Acute cellular rejection (ACR) accounts for 15-25% of graft failure in living donor liver transplantation (LDLT). T regulatory cells (Treg) play an important role…
2015 American Transplant Congress
CD3+CD4+ROR gamma t+ TH17 Cells Do Not Play a Critical Role in Islet Allograft Rejection
M. Koulmanda, Z. Fan.
Medicine, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA.
We have developed a “color-coded” adoptive transfer model for T cell subset identification that enables serial analysis of islet allograft infiltrating yellow induced regulatory T…
2015 American Transplant Congress
Eculizumab in Prevention of Acute Antibody-Mediated Rejection in Sensitized Deceased-Donor Kidney Transplant Recipients: 1-Year Outcomes
D. Glotz,¹ G. Russ,² L. Rostaing,³ C. Legendre,⁴ S. Chadban,⁵ J. Grinyo,⁶ N. Mamode,⁷ E. Cozzi,¹¹ Y. Lebranchu,⁸ S. Sandrini,⁹ L. Couzi,¹² W. Marks.¹⁰
¹H St-Louis, Paris, France; ²Ryl Adelaide H, Adelaide, Australia; ³CHU Rangueil, Toulouse, France; ⁴H Necker, Paris, France; ⁵Ryl Pr Alfred H, Camperdown, Australia; ⁶H U deBellvitge, Barcelona, Spain; ⁷Guy's H, London, United Kingdom; ⁸H Bretonneau CHU, Tours, France; ⁹Spedali Cvl di Brescia, Brescia, Italy; ¹⁰Alexion, Cheshire; ¹¹Via Giustiniani, Padua, Italy; ¹²Hopital Pellegrin, CHU Bordeaux, Bordeaux, France.
Complement activation by preformed DSA is a major mechanism of acute antibody-mediated rejection (aAMR) in sensitized kidney transplant recipients (KTR). We previously reported interim study…
2015 American Transplant Congress
Are AT1R Antibodies as Dangerous as HLA-DSAs in Renal Allografts?
E. Cuevas, J. Arreola-Guerra, E. Hernandez-Mendez, I. Salcedo, M. Vilatoba, A. Contreras, A. Sanchez-Cedillo, J. Ramirez, D. de Rungs, J. Granados, L. Morales-Buenrostro, J. Alberu.
1Transplantation, 1aNephrology-Mineral Metabolism, Inst Nal de Ciencias Medicas y Nutricion SZ, Mexico City, Distrito Federal, Mexico.
Angiotensin II type 1 receptor antibodies (AT1Rab) have been associated with a significantly lower graft survival and a higher risk of acute rejection after kidney…
2015 American Transplant Congress
Association of De Novo Antibody-Mediated Rejection and Increased Hospital Costs Following Kidney Transplant in Immunologically Low-Risk Patients
S. Kulkarni,¹ I. Hall.²
¹Section of Organ Transplantation & Immunology, Yale University, New Haven, CT; ²Section of Nephrology, Yale University, New Haven, CT.
While antibody-mediated rejection (AMR) is likely the primary cause of kidney transplant (KTx) failure, and its treatment can be considered expensive, incremental center costs for…
2015 American Transplant Congress
The Best Regimen With Rituximab for ABO-Incompatible Living Donor Liver Transplantation
H. Egawa,¹ K. Umeshita,² S. Uemoto.³
¹Surgery, Tokyo Women's Medical University, Tokyo, Japan; ²Osaka University, Suita, Japan; ³Kyoto University, Kyoto, Japan.
Rituximab made a great progress on outcomes of ABO-incompatible living donor liver transplantation (ABO-I LDLT). Although Japanese multicenter study group published efficacy and safety of…
2015 American Transplant Congress
Burden of Early Antibody-Mediated Rejection (AMR): Complications, Resource Utilization and Cost-Differential in Treatment of AMR
R. Banga,¹ C. Schinstock,¹ A. Boscoe,⁴ M. Hathcock,³ W. Kremers,³ M. Stegall.²
¹Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN; ²Division of Transplantation Surgery, Mayo Clinic, Rochester, MN; ³Division of Biostatistics, Mayo Clinic, Rochester, MN; ⁴Health Outcomes Research, Alexion Pharmaceuticals, Cheshire, CT.
Early antibody-mediated rejection (AMR) is common in positive crossmatch kidney transplants (+XMKTx). The current study determined the complications, resource utilization and cost associated with early,…
2015 American Transplant Congress
Interrogation of Plasma Cell-Rich Acute Rejection in Human Kidney Allografts by Whole Transcriptome Sequencing
L. Mesnard, F. Campagne, H. Yang, D. Dadhania, J. Lee, S. Seshan, M. Suthanthiran, T. Muthukumar.
Weill Medical College of Cornell University, New York.
Plasma cell-rich acute rejection (PCRAR, plasma cells constituting >20% of the allograft infiltrating cells) portends poor prognosis.To gain better mechanistic insights and develop diagnostic biomarkers,…